

- agement of superficial fungal infections. *Drugs* 1996; 51: 585-620
55. Prentice AG, Warnock DW, Johnson SAN, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. *J Antimicrob Chemother* 1994; 34: 247-52
56. Vandewoude K, Vogelaers D, Decruyenaere J, et al. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. *Antimicrob Agents Chemother* 1997; 41: 2714-8
57. Graybill JR. Is there a correlation between serum antifungal drug concentration and clinical outcome? *J Infect* 1994; 28 Suppl. 1: 17-24
58. British Society for Antimicrobial Chemotherapy Working Party. Laboratory monitoring of antifungal chemotherapy. *Lancet* 1991; 337: 1577-80
59. Working Party of the British Society for Antimicrobial Chemotherapy. Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: a review and recommendations. *J Antimicrob Chemother* 1993; 32: 5-21

Correspondence and reprints: Dr *Georges Cheymol*, Department of Pharmacology, Saint-Antoine Hospital, 184 rue du Faubourg Saint-Antoine, 75571 Paris Cedex 12, France.
E-mail: jpoirier@ccr.jussieu.fr

Erratum

Vol. 35, No. 4, page 277: In table I, row 6, column 7, the figure 0.77 should read *NA*. And in row 6, column 9, *NA* should read 0.77.

[*Hsu A, Granneman GR, Bertz RJ. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet* 1998 Oct; 35 (4): 275-291]